Drug-device combination products are used in the treatment and management of various diseases such as cancer, heart disease, multiple sclerosis, cerebral palsy, spinal-cord injuries, anemia, hepatitis, rheumatoid arthritis, diabetes, and other chronic disorders.
The global drug-device combination products market is estimated to account for US$ 124.3 Bn in terms of value in 2020 and is expected to reach US$ 214.1 Bn by the end of 2027.
Global Drug-Device Combination Products Market: Drivers
Approval and availability of drug-device combination products is expected to propel growth of the global drug-device combination products market over the forecast period. For instance, in July 2019, Walgreens, a pharmacy store chain, and Kaléo, a privately-held pharmaceutical company, announced AUVI-q (epinephrine injection, USP) 0.1 mg auto-injector – the first and only epinephrine auto-injector approved by the U.S. FDA for infants and toddlers is available at Walgreens locations.
Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/3919
Global Drug-Device Combination Products Market: Opportunities
R&D in combination products is expected to offer lucrative growth opportunities for players in the global drug-device combination products market. For instance, in November 2019, Boston Scientific Corporation announced positive data for Eluvia Drug-Eluting Vascular Stent for the treatment of femoropopliteal disease.
Global Drug-Device Combination Products Market: Restraints
Product recalls are expected to hinder growth of the market. For instance, in October 2019, Medtronic plc recalled Medtronic SynchroMed II implantable drug infusion pump due to potential presence of foreign particles inside the pump motor assembly.
We value your investment and offer customization as per your requirements.
Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/3919
The global drug-device combination products market was valued at US$ 115.0 Bn in 2019 and is forecast to reach a value of US$ 214.1 Bn by 2027 at a CAGR of 8.1% between 2020 and 2027. Major factor driving the growth of global drug-device combination products market during the forecast period increasing prevalence of chronic diseases, and product launches.
North America held dominant position in the global drug-device combination products market in 2019, accounting for 41.4% share in terms of value, followed by Europe and Asia Pacific, respectively. Presence of leading manufacturers and product launches is expected to support growth of the market over the forecast period.
Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in February 2020, Integer Holdings Corporation acquired Inomec, an Israel-based manufacturer of medical devices, including minimally invasive tools, delivery systems, metal implants, drug-device combination devices, and laser processing services.
Major players in the market are also focused on conducting clinical trials for approval and launch of new products. For instance, in July 2019, SINOMED completed enrollment in the PIONEER III randomized, controlled clinical trial to assess the safety and effectiveness of the BuMA Supreme DES in order to obtain key regulatory approvals for the BuMA Supreme Drug-Eluting Stent (DES) System.
Global Drug-Device Combination Products Market: Competitive Landscape
Major players operating in the global drug-device combination products market include, Teva Pharmaceutical Industries Ltd., Becton, Dickinson and Company, Integer Holdings Corporation, Abbott Laboratories, Medtronic plc, Allergan, Inc., Alcon, Inc., Arrow International, Inc., Bausch & Lomb, Inc., Boston Scientific Corporation, ALK, SINOMED, Kaléo, Haselmeier, Flowonix Medical, Inc., CareFusion Corporation, and Covidien PLC.
Global Drug-Device Combination Products Market: Key Developments
December 2019: Kaléo collaborated with HealthFirst and MedAire, emergency medical kit distributors, to offer Auvi-Q 0.3 mg and Auvi-Q 0.15 mg auto-injectors in the American Airlines’ emergency medical kits
August 2019: ALK launched new epinephrine auto-injector that is designed to be small, easy-to-use, heat-stable, and with a long shelf life, in the U.S.
Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/3919
- By Product Type
- Drug Eluting Stents
- Infusion pumps
- Orthopedic combination products (Bone graft imlants + antibiotic loaded bone cements)
- Wound care combination products
- Transdermal patches
- Others( Intraocular implants, drug eluting beads)
- By Region
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027